Abstract:
The invention relates to Guanabenz or an analogue thereof for use in the treatment and to methods of treatment of a subject that has vanishing white matter (VWM), comprising administering the compound Guanabenz or an analogue thereof to the subject in need thereof. Also provided are methods with which the success of a medical intervention in a subject with VWM can be determined. Such methods comprise quantifying the translocation of Bergmann glia into the molecular layer in the cerebellum in a suitable sample of the sub ject. The sample is typically a post mortem sample.
Abstract:
The invention provides methods of administering immunotherapy that modulates an interaction between PD- i and its ligand, to a cancer patient, based on tumor-educated gene expression profiles obtained from anucleated cells. The invention further provides methods of typing a sample of a subject for the presence or absence of a cancer, based on tumor- educated gene expression profiles obtained from anucleated cells. The invention further provides a method for obtaining a biomarker panel for typing of a sample from a subject using particle swarm optimization-based algorithms.
Abstract:
The invention relates to a method, system and computer readable medium for determining a strabismus angle of the eyes of an individual by: positioning the individual with his or her eyes in front of an eye tracker device and in front of a screen at a viewing distance; displaying a small image element on the screen; measuring a position and line of sight of the eyes of the individual with the eye tracker device while the individual is focussing on the small image element; forwarding the measured position and line of sight of the eyes from the eye tracker device to a computer system; and, calculating the strabismus angle between the eyes by calculating the difference in line of sight of the left and right eyes of the individual.
Abstract:
The invention relates to means and methods for detecting or determining the level of nucleic acid in urine of a human subject, the method comprising the steps of collecting nucleic acid from a sample of at least 1.0 ml, preferably at least 20 ml of urine of said subject, processing the sample to isolate cell free nucleic acid enriched for fragments of 150 nucleic acid bases or less, and determining whether the enriched nucleic acid comprises methylated nucleic acid of the SEPTIN-9 gene or a promoter region thereof and methylated nucleic acid of the SDC2 gene or a promoter region thereof. The means and methods may be used to arrive at a diagnosis of colorectal cancer, colorectal metastasis, recurrent colorectal cancer or a combination thereof in the human subject. The invention further relates to methods of treatment of human subjects with colorectal cancer, colorectal metastasis, recurrent colorectal cancer or a combination thereof comprising using the means and methods.
Abstract:
The invention relates to an isotope-containing tag, a method of preparing an isotope-containing tag, a tracer comprising an isotope-containing tag, a method of preparing a tracer, a method of labeling biological material, a use of the isotope-containing tag, a kit-of-parts for preparing a tracer. The isotope-containing tag comprises a monodisperse backbone to which at least one ligand and at least one functional group for attaching the backbone to a macromolecule are attached, wherein essentially every ligand attached to the backbone comprises an isotope.
Abstract:
The invention relates to compounds and pharmaceutically acceptable salts thereof, and to their medical use. Exemplary medical uses are the prevention and treatment of a bacterial infection, for example, a mycobacterial infection, such as a Mycobacterium tuberculosis infection, e.g., in a respiratory system and/or extrapulmonic. The invention further relates to a use of such compounds, pharmaceutically acceptable salts thereof or prodrugs of the compounds as chemotherapeutic agents. Also, the invention relates to a use of such compounds, pharmaceutically acceptable salts thereof or prodrugs of the compounds for inhibiting mycobacterial type VII secretion. The compounds have the following formula (Ia), wherein Q and X are, respectively, CH and C, CR2 and C, CH and N, CR2 and N, or N and C; R1 is hydrogen, halide or optionally substituted linear or branched alkoxy having 1 or 2 carbon atoms; R2 is independently selected from hydrogen, halide or optionally substituted linear or branched alkoxy having 1 or 2 carbon atoms, and R3 is optionally substituted linear or branched alkoxy having 1-6 carbon atoms, haloalkyl having 1-6 carbon atoms, n-propyl, 2-propenyl, 2-propynyl, or n-pentyl, or a pharmaceutically acceptable salt of the compound, for use in the prevention or treatment of a bacterial infection.
Abstract:
The invention relates to methods of typing an individual as suffering from, or at risk of suffering from, atrial fibrillation, comprising the steps of providing a bodily fluid from said individual and quantifying a biomarker in said bodily fluid. The invention further relates to methods for assigning standard-of-care therapy to an individual that is typed as suffering from, or at risk of suffering from, atrial fibrillation, according to the methods of typing of the invention, and to a standard- of-care therapy for use in a method of treating an individual that is typed as suffering from, or at risk of suffering from, atrial fibrillation, according to the methods of the invention.
Abstract:
The present application relates to bispecific antibodies, either BCMA*CD3 or GRRC5D*CD3. The bispecific antibodies are to be used in the treatment of refractory cancers, especially after a previous treatment with an anti CD38-antibody.